SCHEMBL5380205

SCHEMBL5380205

Cc1ccc(F)cc1C1(O)CCN(C(=O)O)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 2/20 0.49
DRD4 P21917 2/20 0.49
DRD3 P35462 2/20 0.49
HDAC4 P56524 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
OPRM1 P35372 1/20 0.39
OPRD1 P41143 1/20 0.39
OPRK1 P41145 1/20 0.39
OPRL1 P41146 1/20 0.39
MC4R P32245 1/20 0.38
CCR1 P32246 1/20 0.38
PSEN1 P49768 2/20 0.37
PSEN2 P49810 2/20 0.37
APH1B Q8WW43 2/20 0.37
NCSTN Q92542 2/20 0.37
APH1A Q96BI3 2/20 0.37
PSENEN Q9NZ42 2/20 0.37
AKR1B1 P15121 2/20 0.36
MAPK1 P28482 1/20 0.36
S1PR2 O95136 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5368473 0.85 DRD2 (0.55) DRD2DRD4DRD3L3MBTL1OPRM1
SCHEMBL3384864 0.82 CNR1 (0.46) DRD2OPRM1OPRD1OPRK1OPRL1
SCHEMBL5371445 0.82 L3MBTL1 (0.44) DRD2DRD4DRD3L3MBTL1OPRM1
SCHEMBL6002487 0.79 OPRM1 (0.40) DRD2DRD4DRD3HDAC4L3MBTL1
SCHEMBL5373284 0.79 OPRM1 (0.60) HDAC4L3MBTL1OPRM1OPRD1OPRK1
SCHEMBL5379982 0.77 AKR1B10 (0.47) L3MBTL1OPRM1OPRD1OPRK1OPRL1
SCHEMBL5375989 0.77 DRD2 (0.44) DRD2DRD4DRD3L3MBTL1OPRM1
SCHEMBL11825300 0.76 HDAC4 (0.48) DRD2DRD4DRD3HDAC4L3MBTL1
SCHEMBL6967833 0.76 OPRL1 (0.56) DRD2DRD4DRD3OPRL1MAPK1
SCHEMBL4725181 0.75 OPRM1 (0.55) DRD2DRD4DRD3OPRM1OPRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1714961-B1 INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2015-12-09 EP claimed
US-20070173537-A1 Indazole compound and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2007-07-26 US claimed
EP-1714961-A1 INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2006-10-25 EP claimed
EP-1714961-B1 INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2015-12-09 EP disclosed
US-20070173537-A1 Indazole compound and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2007-07-26 US disclosed
EP-1714961-A1 INDAZOLE COMPOUND AND PHARMACEUTICAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2006-10-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070173537-A1 Indazole compound and pharmaceutical use thereof CYP3A5, CYP3A43, TP53 DRD2 3805/4885DRD4 4276/4885DRD3 3346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.